Inventor
Joseph Schlessinger
Inventor
New York, NY, US
Overview
Patents· 49 as inventor
Public. Assignee & technology derived from the patent record. Each patent links to its LexDana page.
C07Kprimary
C07KPeptides31%
A61KPreparations for medical, dental or toiletry purposes20%
C12NMicroorganisms or enzymes17%
G01NInvestigating or analysing materials by determining their chemical or physical properties16%
A61PSpecific therapeutic activity of chemical compounds or medicinal preparations12%
C12QMeasuring or testing processes involving enzymes, nucleic acids or microorganisms1%
C07CAcyclic or carbocyclic compounds1%
H10PGeneric processes or apparatus for the manufacture or treatment of devices covered by class h101%
Y10STechnical subjects covered by former uspc cross-reference art collections [xracs] and digests1%
PatentTitleYear
10,793,639Methods of treating by administering anti-kit antibodies202010,745,490Anti-ErbB antibodies and methods of use thereof202010,189,907Polynucleotides encoding anti-KIT antibodies20199,540,443'Anti-kit antibodies'20179,273,134'Inhibitors of receptor tyrosine kinases and methods of use thereof'20167,872,016'Method for treating skeletal disorders resulting from FGFR malfunction'20117,314,620'Methods for diagnosis and treatment of PH domain signal transduction disorders'20087,135,320'Adaptor protein FRS2 and related products and methods'20067,129,072'Crystal of fibroblast growth factor receptor 1 in complex with fibroblast growth factor'20067,108,994'Receptor-type phosphotyrosine phosphatase-alpha'20067,056,508'Receptor-type phosphotyrosine phosphatase-kappa antibodies'20066,861,442'PYK2 and inflammation'20056,803,452'RPTP- antibodies'20046,682,921'Crystals of the tyrosine kinase domain of non-insulin receptor tyrosine kinases'20046,682,905'Receptor-type phosphotyrosine phosphatase-alpha'20046,576,442'rdgB proteins and related products and methods'20036,528,270'Methods for identifying compounds for treatment of cell proliferative disorders associated with adaptor protein interactions'20036,391,584'Expression-cloning method for identifying target proteins for eukaryotic tyrosine kinases and novel target proteins'20026,344,546'Fibroblast growth factor receptors'20026,310,181'Adaptor protein FRS2 and related products and methods'20016,217,866'Monoclonal antibodies specific to human epidermal growth factor receptor and therapeutic methods employing same'20016,160,090'Receptor protein tyrosine phosphatases'20006,117,673'RDGB proteins and related products and methods'20006,066,463'Method and compositions for treatment of BCR-ABL associated leukemias and other cell proliferative disorders'20006,054,280'Methods for diagnosis and treatment of PH domain signal transduction disorders'20006,045,797'Treatment or diagnosis of diseases or conditions associated with a BLM domain'20005,942,428'Crystals of the tyrosine kinase domain of non-insulin receptor tyrosine kinases'19995,925,536'Receptor-type phosphotyrosine phosphatase-.beta.'19995,891,700'Receptor-type phosphotyrosine phosphatase-.gamma.'19995,889,150'Expression-cloning method for identifying target proteins for eukaryotic tyrosine kinases and novel target protiens'19995,888,794'Receptor-type phosphotyrosine phosphatase-alpha'19995,863,755'Nucleic acid encoding novel receptor-type phosphotyrosine phosphatase-.kappa.'19995,863,888'Human Bek Fibroblast growth factor receptor'19995,861,266'Treatment of diabetes mellitus and insulin receptor signal transduction'19995,858,686'Methods for detecting tyrosine kinase-binding target proteins and identifying substances that affect SH2 phosphorylated ligand regulatory systems'19995,856,162'Receptor-type phosphotyrosine phosphatase-.kappa.'19995,846,800'Nucleic acid molecules encoding a novel receptor-type protein tyrosine phosphatase-.sigma.'19985,840,842'Receptor-type phosphotyrosine phosphatase-sigma'19985,837,815'PYK2 related polypeptide products'19985,837,524'PYK2 related polynucleotide products'19985,807,989'Methods for treatment or diagnosis of diseases or disorders associated with an APB domain'19985,783,568'Methods for treating cancer and other cell proliferative diseases'19985,677,421'Target proteins for eukaryotic tyrosine kinases'19975,618,691'Recombinant DNA encoding a eukaryotic tyrosine kinase target protein'19975,604,094'Receptor-type phosphotyrosine phosphatase-.beta.'19975,538,886'Receptor-type phosphotyrosine phosphatase-alpha'19965,532,123'Receptor-type phosphotyrosine phosphatase-.gamma.'19965,434,064'Expression-cloning method for identifying target proteins for eukaryotic tyrosine kinases and novel target proteins'19954,933,294'Method of detecting truncated epidermal growth factor receptors'1990Career & activity timeline
Assembled from patent assignee/location history and declaration credentials.
1990Based in Rehovot, IL· patent location history
1995–2008Patents assigned to UNIV NEW YORK (27)· patent assignee history
1995–2006Based in New York, NY, US· patent location history
1998–2005Patents assigned to SUGEN INC (9)· patent assignee history
1999–2002Patents assigned to UNIV NEW YORK MED CT (5)· patent assignee history
1999–2002Based in Wayne, PA, US· patent location history
2003Based in San Carlos, CA, US· patent location history
2006–2020Based in Woodbridge, CT, US· patent location history
2011–2020Patents assigned to UNIV YALE (3)· patent assignee history
2019–2020Patents assigned to CELLDEX THERAPEUTICS INC (3)· patent assignee history
Inventor activity
Assignee and location history derived from the patent record.
Assignees
| Assignee | Patents | Span |
|---|---|---|
| UNIV NEW YORK | 27 | 1995–2008 |
| SUGEN INC | 9 | 1998–2005 |
| UNIV NEW YORK MED CT | 5 | 1999–2002 |
| CELLDEX THERAPEUTICS INC | 3 | 2019–2020 |
| UNIV YALE | 3 | 2011–2020 |
Locations
| Location | Patents | Span |
|---|---|---|
| New York, New York, US | 37 | 1995–2006 |
| Woodbridge, CT, US | 8 | 2006–2020 |
| Wayne, Pennsylvania, US | 2 | 1999–2002 |
| San Carlos, California, US | 1 | 2003 |
| Rehovot, IL | 1 | 1990 |